Ironwood Pharmaceuticals (IRWD) Expected to Announce Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Ironwood Pharmaceuticals to announce earnings of $0.3233 per share and revenue of $119.99 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. On average, analysts expect Ironwood Pharmaceuticals to post $1.10 EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ:IRWD traded down $0.04 during mid-day trading on Tuesday, reaching $3.42. The stock had a trading volume of 234,590 shares, compared to its average volume of 2,864,442. The firm has a market cap of $564.29 million, a PE ratio of 4.44 and a beta of 0.21. The firm has a 50 day simple moving average of $3.94 and a two-hundred day simple moving average of $3.98. Ironwood Pharmaceuticals has a twelve month low of $1.76 and a twelve month high of $5.78.

Analyst Ratings Changes

Several brokerages have commented on IRWD. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. Wall Street Zen lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.